Buy Semaglutide
Buy Semaglutide, a synthetic GLP-1 receptor agonist peptide studied for metabolic regulation and incretin signaling pathways. 10mg lyophilized powder, 99%+ purity verified by Janoshik Analytical via HPLC and mass spectrometry. CAS 910463-68-2.
-
For laboratory research use only.
-
Not for human or veterinary use.
-
Not intended for diagnosis, treatment, cure, or prevention of any disease.
-
Use only in controlled laboratory settings by qualified personnel following appropriate safety procedures.
Semaglutide has been widely discussed across mainstream media and health communities for its role in metabolic function studies. It is frequently compared with Tirzepatide (a dual GIP/GLP-1 agonist) and Retatrutide (a triple agonist) in research settings exploring GLP-1 agonist efficacy differences. Durham Peptides carries all three compounds.
BENEFITS
-
Metabolic research — studied for effects on GLP-1 receptor activation and glucose regulation
-
Weight management — explored extensively in clinical trial settings for body composition changes
-
Appetite signaling — linked to modulation of satiety and hunger pathways
-
Cardiovascular — associated with cardiovascular outcome studies in large-scale trials
-
Pancreatic function — investigated for beta-cell preservation and insulin secretion pathways
WHAT RESEARCHERS LOOK AT
-
GLP-1 receptor binding affinity and activation kinetics
-
Comparative efficacy with other GLP-1 agonists (liraglutide, tirzepatide)
-
Dose-response curves in metabolic models
-
Half-life extension through albumin binding
-
Appetite regulation via central and peripheral signaling
QUICK SPECS
-
Form: Lyophilized peptide powder
-
Net per vial: 10 mg
-
Purity: ≥99% (HPLC verified)
-
Identity: MS-verified (per COA)
-
Storage: 2–8°C, protect from light and moisture
-
Reconstitution: Use bacteriostatic water (sold separately)
IDENTITY BASICS
-
Molecular Formula: C₁₈₇H₂₉₁N₄₅O₅₉
-
Molecular Weight: 4113.58 g/mol
-
CAS: 910463-68-2
-
Classification: GLP-1 receptor agonist




Reviews
There are no reviews yet.